MN-ASI-DATAMYTE
11.12.2015 11:01:06 CET | Business Wire | Press release
ASI DATAMYTE, Inc., the leader in global quality management solutions, announces today a multinational partnership with NEXTSENSE GmbH, the leader in the production of laser-based profile measurement solutions for manufacturers, worldwide. The automotive industry is evolving with more complex designs using a broader variety of materials; which is creating the need for a more comprehensive measurement solutions for ensuring accuracy, inspection thoroughness and operator repeatability. As part of this new relationship, ASI DATAMYTE will now support this market need by offering CALIPRI product line to the automotive industry.
“CALIPRI is one of the fastest-growing, scalable, non-contact measurement solutions in the market,” said Sven Tetzlaff, ASI DATAMYTE GmbH head of product and general manager. “We are confident the combination of CALIPRI and our expertise, technology and client base, creates unmatched value for automotive companies looking to produce higher quality products. We will now have a streamlined solution using one technology supporting the inline and automated measurement throughout the production process.”
“We are committed to continuing our investments and innovation in our state-of-the-art optical sensor technology that will empower the future of ASI DATAMYTE’s clients and distributors,” said Clemens Gasser, chief executive officer, NEXTSENSE GmbH. “We are looking forward to watching our partnership redefine quality measurement and data collection across the globe.”
About ASI DATAMYTE
ASI DATAMYTE Inc. provides integrated software, hardware and services for driving best-in-class quality in manufacturing. Refining its solutions for more than 40 years, ASI DATAMYTE is serving the largest, most prestigious manufacturers with localized solutions on a global basis. ASI DATAMYTE is headquartered in Plymouth, MN, with offices and support centers in more than 40 countries.
About NEXTSENSE
NEXTSENSE GmbH is a global leader in producing and distributing revolutionary solutions for profile measurement and surface inspection, called CALIPRI and SURFILES. All solutions are based on non-contact measurement technology which captures unbiased measurement data removing all outside variables based on differences between operators or environmental conditions. NEXTSENSE devices are used for gap and flush measurement of automotive bodies, wear measurement of railway wheelsets and analyzing the surfaces of rolled steel. The client list ranges from international automobile manufactures (e.g. Volkswagen, Toyota, General Motors) to well-known international enterprises in the railway, steel and technology industry such as SNCF, AcelorMittal and Miele).
View source version on businesswire.com: http://www.businesswire.com/news/home/20151211005140/en/
Contact:
ASI DATAMYTE Inc.
Mary Braunwarth
mary.braunwarth@asidatamyte.com
+1.763.553.0455
info@asidatamyte.com
www.asidatamyte.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
